<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName journalpublishing.dtd?>
  <?SourceDTD.Version 2.0?>
  <?ConverterInfo.XSLTName jp2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Exp Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">exd</journal-id>
      <journal-title-group>
        <journal-title>Experimental Dermatology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0906-6705</issn>
      <issn pub-type="epub">1600-0625</issn>
      <publisher>
        <publisher-name>Blackwell Publishing Ltd</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3068286</article-id>
      <article-id pub-id-type="pmid">20482620</article-id>
      <article-id pub-id-type="doi">10.1111/j.1600-0625.2010.01098.x</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Prostaglandin D<sub>2</sub> production in FM55 melanoma cells is regulated by &#x3B1;-melanocyte-stimulating hormone and is not related to melanin production</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Masoodi</surname>
            <given-names>Mojgan</given-names>
          </name>
          <xref ref-type="aff" rid="au1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nicolaou</surname>
            <given-names>Anna</given-names>
          </name>
          <xref ref-type="aff" rid="au1">1</xref>
          <xref ref-type="aff" rid="au2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gledhill</surname>
            <given-names>Karl</given-names>
          </name>
          <xref ref-type="aff" rid="au2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rhodes</surname>
            <given-names>Lesley E</given-names>
          </name>
          <xref ref-type="aff" rid="au3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tobin</surname>
            <given-names>Desmond J</given-names>
          </name>
          <xref ref-type="aff" rid="au2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thody</surname>
            <given-names>Anthony J</given-names>
          </name>
          <xref ref-type="aff" rid="au4">4</xref>
        </contrib>
        <aff id="au1">
          <label>1</label>
          <institution>Bradford School of Pharmacy, School of Life Sciences, University of Bradford</institution>
          <addr-line>Bradford, UK</addr-line>
        </aff>
        <aff id="au2">
          <label>2</label>
          <institution>Centre for Skin Sciences, School of Life Sciences, University of Bradford</institution>
          <addr-line>Bradford, UK</addr-line>
        </aff>
        <aff id="au3">
          <label>3</label>
          <institution>Dermatological Sciences, School of Translational Medicine, University of Manchester and Salford Royal NHS Foundation Hospital, Manchester Academic Health Sciences Centre</institution>
          <addr-line>Manchester, UK</addr-line>
        </aff>
        <aff id="au4">
          <label>4</label>
          <institution>School of Clinical and Laboratory Sciences, University of Newcastle upon Tyne</institution>
          <addr-line>Newcastle upon Tyne, UK</addr-line>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Professor A Nicolaou, Bradford School of Pharmacy, School of Life Sciences, University of Bradford, Bradford BD7 1DP, UK, Tel.: +44 1274 234717, Fax: +44 1274 235600, e-mail: <email>A.Nicolaou@bradford.ac.uk</email></corresp>
        <fn>
          <p>Re-use of this article is permitted in accordance with the Terms and Conditions set out at <ext-link ext-link-type="uri" xlink:href="http://www3.interscience.wiley.com/authorresources/onlineopen.html">http://www3.interscience.wiley.com/authorresources/onlineopen.html</ext-link></p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>8</month>
        <year>2010</year>
      </pub-date>
      <volume>19</volume>
      <issue>8</issue>
      <fpage>751</fpage>
      <lpage>753</lpage>
      <history>
        <date date-type="accepted">
          <day>23</day>
          <month>3</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2010 John Wiley &amp; Sons A/S</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/">
          <license-p>Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>This study shows that prostaglandins in human FM55 melanoma cells and epidermal melanocytes are produced by COX-1. Prostaglandin production in FM55 melanoma cells was unrelated to that of melanin suggesting that the two processes can occur independently. &#x3B1;-Melanocyte-stimulating hormone, which had no effect on melanin production in FM55 cells, stimulated PGD<sub>2</sub> production in these cells without affecting PGE<sub>2</sub>. While cAMP pathways may be involved in regulating PGD<sub>2</sub> production, our results suggest that &#x3B1;-MSH acts independently of cAMP, possibly by regulating the activity of lipocalin-type PGD synthase. This &#x3B1;-MSH-mediated effect may be associated with its role as an immune modulator.</p>
      </abstract>
      <kwd-group>
        <kwd>&#x3B1;-melanocyte-stimulating hormone</kwd>
        <kwd>liquid chromatography electrospray tandem mass spectrometry</kwd>
        <kwd>melanogenesis</kwd>
        <kwd>pigment cells</kwd>
        <kwd>prostaglandin D<sub>2</sub></kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="">
      <title>Background</title>
      <p>Melanocytes produce melanin and have a role in skin pigmentation (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b2">2</xref>). Cutaneous prostaglandins, such as PGE<sub>2</sub> and PGF<sub>2&#x3B1;</sub>, may act as mediators in this process because they increase melanocyte dendricity and melanogenesis (<xref ref-type="bibr" rid="b3">3</xref>,<xref ref-type="bibr" rid="b4">4</xref>). It has been suggested that these prostaglandins arise from keratinocytes (<xref ref-type="bibr" rid="b4">4</xref>) but it is possible that they are also produced by melanocytes acting as autocrine factors in the pigmentary response.</p>
      <p>However, prostaglandins have a wide range of biological activities, and while some such as PGE<sub>2</sub> act as pro-inflammatory mediators (<xref ref-type="bibr" rid="b5">5</xref>), others such as PGD<sub>2</sub> down-regulate immune responses (<xref ref-type="bibr" rid="b6">6</xref>). PGD<sub>2</sub> is formed by prostaglandin D synthase (EC 5.3.99.2) (PGDS), an isoform of which, lipocalin-PGDS (L-PGDS), is expressed in pigment cells (<xref ref-type="bibr" rid="b7">7</xref>). Expression of L-PGDS is dependent upon microphthalmia-associated transcription factor (MITF) (<xref ref-type="bibr" rid="b7">7</xref>) which is activated via cAMP and is involved in regulating melanogenesis (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b9">9</xref>). Thus, it is possible that PGD<sub>2</sub> production is associated with melanogenesis, and the two processes have a common regulatory pathway.</p>
      <p>&#x3B1;-Melanocyte-stimulating hormone (&#x3B1;-MSH) regulates melanogenesis via the cAMP-coupled melanocortin 1 receptor (MC1R) expressed on melanocytes (<xref ref-type="bibr" rid="b10">10</xref>&#x2013;<xref ref-type="bibr" rid="b12">12</xref>). This peptide is also a potent immunomodulator through its effects on MC1R expressing immune cells such as monocytes and macrophages (<xref ref-type="bibr" rid="b13">13</xref>). Because melanocytes are immunocompetent (<xref ref-type="bibr" rid="b14">14</xref>&#x2013;<xref ref-type="bibr" rid="b16">16</xref>), they might also mediate immunomodulatory actions of &#x3B1;-MSH. Their production of prostaglandins and, specifically, PGD<sub>2</sub> could therefore be associated with this function.</p>
    </sec>
    <sec sec-type="">
      <title>Questions addressed</title>
      <p>Is the production of prostaglandins related to that of melanin in pigment-producing cells, and is it regulated by &#x3B1;-MSH?</p>
    </sec>
    <sec sec-type="">
      <title>Experimental design</title>
      <p>Prostaglandins were measured in melanin-producing FM55 human melanoma cells (<xref ref-type="bibr" rid="b17">17</xref>) and in human epidermal melanocytes. FM55 cells were used as a model system to examine the relationship between prostaglandin and melanin production and the effect of &#x3B1;-MSH. Because their MC1R does not couple to cAMP FM55 cells do not produce melanin in response to &#x3B1;-MSH (<xref ref-type="bibr" rid="b18">18</xref>). Their use therefore allowed the possibility of dissociating prostaglandin production from that of melanin.</p>
      <p>The lightly pigmented FM55 cells were established from metastatic melanoma nodules (Dr AF Kirkin, Danish Cancer Society, Copenhagen, Denmark). Human epidermal melanocytes were isolated from skin samples obtained with local ethics committee approval and informed consent from donors undergoing elective plastic surgery. Cell culture (<xref ref-type="bibr" rid="b19">19</xref>,<xref ref-type="bibr" rid="b20">20</xref>), eicosanoid analysis (<xref ref-type="bibr" rid="b21">21</xref>), stimulation and measurement of melanin (<xref ref-type="bibr" rid="b20">20</xref>,<xref ref-type="bibr" rid="b22">22</xref>) and COX-1/-2 protein expression (<xref ref-type="bibr" rid="b5">5</xref>) were performed as published; L-PGDS was measured using an immunometric kit (<xref ref-type="supplementary-material" rid="SD1">Appendix S1</xref>).</p>
    </sec>
    <sec sec-type="">
      <title>Results</title>
      <p>PGD<sub>2</sub> and PGE<sub>2</sub> were the major prostaglandins identified in human epidermal melanocytes and FM55 melanoma cells (<xref ref-type="fig" rid="fig01">Fig. 1a, b</xref>). Lipidomic analysis did not confirm production of PGF<sub>2&#x3B1;</sub> by FM55, as previously reported using a less specific radiometric approach (<xref ref-type="bibr" rid="b17">17</xref>). Western blotting analysis revealed that FM55 cells and melanocytes expressed the constitutive isoform of cyclooxygenase (COX-1) but not the inducible isoform COX-2 (<xref ref-type="fig" rid="fig01">Fig. 1c, d</xref>).</p>
      <fig id="fig01" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Sample profile of prostaglandins (PG) produced by human epidermal melanocytes F39 (a) and human melanoma FM55 (b) under resting conditions (Control) and following treatment with arachidonic acid (AA) (10 &#x3BC;<sc>m</sc> for 24 h). Expression of COX-1 and COX-2 proteins in human epidermal melanocytes F39 (c) and human melanoma FM55 cells (d) assessed by Western blotting analysis. MW: molecular weight markers; Lane 1: COX-1; Lane 2: COX-1+ COX-1 blocking peptide; Lane 3: COX-2; Lane 4: COX-2-positive control using FM3 hamster melanoma cells. Note: each antibody (i.e. COX-1 and COX-2) was independently carried on its own lane of the same gel. Data shown as mean &#xB1; SEM of <italic>n</italic> = 3 independent experiments. *<italic>P</italic>&lt; 0.05 and **<italic>P</italic> &lt; 0.005, comparing data to control.</p>
        </caption>
        <graphic xlink:href="exd0019-0751-f1"/>
      </fig>
      <p>Increasing melanin production in FM55 had no effect on prostaglandin production (<xref ref-type="fig" rid="fig02">Fig. 2a, b</xref>); when prostaglandins were stimulated with arachidonic acid, melanin production was not affected (23 &#xB1; 6 and 24 &#xB1; 4 &#x3BC;g melanin/mg cell protein, before and after treatment, respectively).</p>
      <fig id="fig02" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Prostaglandin (PG) and melanin production in FM55 human melanoma cells. The effect of NH<sub>4</sub>Cl (10 m<sc>m</sc>) and <sc>l</sc>-tyrosine (400 &#x3BC;<sc>m</sc>) on (a) melanogenesis and (b) prostaglandin production. (c) The effect of &#x3B1;-Melanocyte-stimulating hormone (&#x3B1;-MSH) (10<sup>&#x2212;8</sup> <sc>m</sc>) and IBMX (10<sup>&#x2212;4</sup> <sc>m</sc>) on cell number, levels of melanin, PGD<sub>1</sub>, PGD<sub>2</sub> and PGE<sub>2</sub>, following 48-h treatment. Dose-dependent effect of &#x3B1;-MSH (10<sup>&#x2212;10</sup>&#x2013;10<sup>&#x2212;7</sup> <sc>m</sc>) on (d) PGD<sub>1</sub> and PGD<sub>2</sub> production and (e) lipocalin-prostaglandin D synthase expression. Data expressed as mean &#xB1; SEM of <italic>n</italic> = 3 independent experiments. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01 and ***<italic>P</italic> &lt; 0.001 comparing data to control (CTR). (f) Schematic outline of the major signalling pathways involved in melanin and PGD<sub>2</sub> production. In FM55 cells, the MC1R does not couple to cAMP as indicated by the cross. As a consequence, &#x3B1;-MSH fails to stimulate melanin production, and the regulation of PGD<sub>2</sub> production may be via a cAMP independent pathway as indicated by the dotted line. AA, arachidonic acid; PGH<sub>2</sub>, prostaglandin H<sub>2</sub>; MC1R, melanocortin 1 receptor; MITF, microphthalmia-associated transcription factor.</p>
        </caption>
        <graphic xlink:href="exd0019-0751-f2"/>
      </fig>
      <p>&#x3B1;-MSH had no effect on PGE<sub>2</sub> production in FM55 cells but increased PGD<sub>2</sub> and PGD<sub>1</sub> with no effect on melanin (<xref ref-type="fig" rid="fig02">Fig. 2c</xref>). 3-Isobutyl-1-methylxanthine (IBMX), which raises cAMP levels by inhibiting phosphodiesterase, increased the production of PGD<sub>2</sub> and, in contrast to &#x3B1;-MSH, increased melanin production (<xref ref-type="fig" rid="fig02">Fig. 2c</xref>). As shown in <xref ref-type="fig" rid="fig02">Fig. 2d</xref>, the effect of &#x3B1;-MSH on PGD<sub>2</sub> production was dose-related, the maximal increase occurring in response to 10<sup>&#x2212;8</sup><sc>m</sc>&#x3B1;-MSH, a dose within the physiological range of concentrations of &#x3B1;-MSH in the epidermis (<xref ref-type="bibr" rid="b2">2</xref>). At 10<sup>&#x2212;7</sup><sc>m</sc>, &#x3B1;-MSH reduced PGD<sub>2</sub> to control levels. Similar changes were seen with PGD<sub>1</sub>. L-PGDS was present in FM55 melanoma cells, but protein levels were unaffected by &#x3B1;-MSH (<xref ref-type="fig" rid="fig02">Fig. 2e</xref>).</p>
    </sec>
    <sec sec-type="">
      <title>Conclusion</title>
      <p>It has been suggested that prostaglandins have a role in the pigmentary response (<xref ref-type="bibr" rid="b3">3</xref>,<xref ref-type="bibr" rid="b4">4</xref>). However, we found no such association between prostaglandin and melanin production in FM55 melanoma cells. This dissociation was further demonstrated in experiments with &#x3B1;-MSH. Although this peptide is melanogenic in human melanocytes via the MC1R (<xref ref-type="bibr" rid="b10">10</xref>,<xref ref-type="bibr" rid="b11">11</xref>), it fails to have this effect in FM55 cells (<xref ref-type="bibr" rid="b18">18</xref>), as confirmed here, yet it increased prostaglandin production. Thus, it would seem that in FM55 cells prostaglandins are produced as part of some non-pigmentary function.</p>
      <p>PGD<sub>2</sub> is a major prostaglandin in both epidermal melanocytes and FM55 cells. &#x3B1;-MSH modulated the production of PGD<sub>2</sub> in a concentration-dependent manner in FM55, producing a bell-shaped dose response curve similar to that observed for melanin (<xref ref-type="bibr" rid="b10">10</xref>) and NO (<xref ref-type="bibr" rid="b15">15</xref>). As with many of its actions, it seems that &#x3B1;-MSH is a modulator rather than an outright stimulator.</p>
      <p>&#x3B1;-MSH may act specifically to regulate PGD<sub>2</sub> synthesis at the level of L-PGDS (<xref ref-type="fig" rid="fig02">Fig. 2f</xref>). This is supported by the concomitant stimulation on PGD<sub>1</sub> but lack of effect on PGE<sub>2</sub>, indicating that &#x3B1;-MSH is not acting at the level of COX. Our findings indicate that &#x3B1;-MSH may affect the activity, but not expression of L-PGDS. Expression of L-PGDS is upregulated by MITF (<xref ref-type="bibr" rid="b7">7</xref>), which is under the control of the cAMP signalling pathway (<xref ref-type="bibr" rid="b23">23</xref>). This would explain the increase in PGD<sub>2</sub> production observed in response to IBMX-dependent increased cAMP. It is unlikely that &#x3B1;-MSH acts in this way because the MC1R on FM55 cells does not couple to cAMP (<xref ref-type="bibr" rid="b18">18</xref>). We therefore propose that &#x3B1;-MSH acts independently of cAMP and activates L-PGDS rather than inducing its expression. Further studies using human epidermal melanocytes and melanoma cells with different degrees of pigmentation are needed to elucidate this effect of &#x3B1;-MSH and determine whether it is a common property of pigment-producing cells.</p>
      <p>PGD<sub>2</sub> can inhibit growth of human melanoma cells (<xref ref-type="bibr" rid="b24">24</xref>) and loss of L-PGDS expression may be important in allowing the tumor to avoid immune surveillance (<xref ref-type="bibr" rid="b25">25</xref>). The fact that PGD<sub>2</sub> is a product of immune cells, such as Langerhans cells, mast cells and macrophages (<xref ref-type="bibr" rid="b26">26</xref>) emphasizes its importance as an immunomodulator. Melanocytes are another potential source of cutaneous PGD<sub>2</sub>; this together with the regulation of PGD<sub>2</sub> production by &#x3B1;-MSH underlines their importance as mediators of immune responses in the skin.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p content-type="acknowledgment">We acknowledge The Wellcome Trust (project number WT077714) for funding this research. The group of LER is supported by the NIHR Manchester Biomedical Research Centre. The authors thank Andrew Healey, University of Bradford Analytical Centre for technical support.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="b1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Slominski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tobin</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Shibahara</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wortsman</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <source>Physiol Rev</source>
          <year>2004</year>
          <volume>84</volume>
          <fpage>1155</fpage>
          <lpage>1228</lpage>
          <pub-id pub-id-type="pmid">15383650</pub-id>
        </element-citation>
      </ref>
      <ref id="b2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thody</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Graham</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <source>Pigment Cell Res</source>
          <year>1998</year>
          <volume>11</volume>
          <fpage>265</fpage>
          <lpage>274</lpage>
          <pub-id pub-id-type="pmid">9877097</pub-id>
        </element-citation>
      </ref>
      <ref id="b3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abdel-Malek</surname>
              <given-names>ZA</given-names>
            </name>
            <name>
              <surname>Swope</surname>
              <given-names>VB</given-names>
            </name>
            <name>
              <surname>Amornsiripanitch</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nordlund</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <source>Cancer Res</source>
          <year>1987</year>
          <volume>47</volume>
          <fpage>3141</fpage>
          <lpage>3146</lpage>
          <pub-id pub-id-type="pmid">2438034</pub-id>
        </element-citation>
      </ref>
      <ref id="b4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scott</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Leopardi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Printup</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Malhi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Seiberg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lapoint</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <source>J Invest Dermatol</source>
          <year>2004</year>
          <volume>122</volume>
          <fpage>1214</fpage>
          <lpage>1224</lpage>
          <pub-id pub-id-type="pmid">15140225</pub-id>
        </element-citation>
      </ref>
      <ref id="b5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rhodes</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Gledhill</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Masoodi</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <source>FASEB J</source>
          <year>2009</year>
          <volume>23</volume>
          <fpage>3947</fpage>
          <lpage>3956</lpage>
          <pub-id pub-id-type="pmid">19584301</pub-id>
        </element-citation>
      </ref>
      <ref id="b6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kabashima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Miyachi</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <source>J Dermatol Sci</source>
          <year>2004</year>
          <volume>34</volume>
          <fpage>177</fpage>
          <lpage>184</lpage>
          <pub-id pub-id-type="pmid">15113587</pub-id>
        </element-citation>
      </ref>
      <ref id="b7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takeda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yokoyama</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aburatani</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Biochem Biophys Res Commun</source>
          <year>2006</year>
          <volume>339</volume>
          <fpage>1098</fpage>
          <lpage>1106</lpage>
          <pub-id pub-id-type="pmid">16337607</pub-id>
        </element-citation>
      </ref>
      <ref id="b8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schallreuter</surname>
              <given-names>KU</given-names>
            </name>
            <name>
              <surname>Kothari</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chavan</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Spencer</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <source>Exp Dermatol</source>
          <year>2008</year>
          <volume>17</volume>
          <fpage>395</fpage>
          <lpage>404</lpage>
          <pub-id pub-id-type="pmid">18177348</pub-id>
        </element-citation>
      </ref>
      <ref id="b9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tachibana</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <source>Pigment Cell Res</source>
          <year>2000</year>
          <volume>13</volume>
          <fpage>230</fpage>
          <lpage>240</lpage>
          <pub-id pub-id-type="pmid">10952390</pub-id>
        </element-citation>
      </ref>
      <ref id="b10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hunt</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Todd</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cresswell</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Thody</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <source>J Cell Sci</source>
          <year>1994</year>
          <volume>107</volume>
          <fpage>205</fpage>
          <lpage>211</lpage>
          <pub-id pub-id-type="pmid">8175909</pub-id>
        </element-citation>
      </ref>
      <ref id="b11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abdel-Malek</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Swope</surname>
              <given-names>VB</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1995</year>
          <volume>92</volume>
          <fpage>1789</fpage>
          <lpage>1793</lpage>
          <pub-id pub-id-type="pmid">7878059</pub-id>
        </element-citation>
      </ref>
      <ref id="b12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsatmali</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ancans</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Thody</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <source>J Histochem Cytochem</source>
          <year>2002</year>
          <volume>50</volume>
          <fpage>125</fpage>
          <lpage>133</lpage>
          <pub-id pub-id-type="pmid">11799132</pub-id>
        </element-citation>
      </ref>
      <ref id="b13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luger</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Scholzen</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Brzoska</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Bohm</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <source>Ann N Y Acad Sci</source>
          <year>2003</year>
          <volume>994</volume>
          <fpage>133</fpage>
          <lpage>140</lpage>
          <pub-id pub-id-type="pmid">12851308</pub-id>
        </element-citation>
      </ref>
      <ref id="b14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smit</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Le Poole</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>van den Wijngaard</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tigges</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Westerhof</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <source>Arch Dermatol Res</source>
          <year>1993</year>
          <volume>285</volume>
          <fpage>356</fpage>
          <lpage>365</lpage>
          <pub-id pub-id-type="pmid">8215585</pub-id>
        </element-citation>
      </ref>
      <ref id="b15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsatmali</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Graham</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Szatkowski</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <source>J Invest Dermatol</source>
          <year>2000</year>
          <volume>114</volume>
          <fpage>520</fpage>
          <lpage>526</lpage>
          <pub-id pub-id-type="pmid">10692112</pub-id>
        </element-citation>
      </ref>
      <ref id="b16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Le Poole</surname>
              <given-names>IC</given-names>
            </name>
            <name>
              <surname>van den Wijngaard</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Westerhof</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Exp Cell Res</source>
          <year>1993</year>
          <volume>205</volume>
          <fpage>388</fpage>
          <lpage>395</lpage>
          <pub-id pub-id-type="pmid">8482344</pub-id>
        </element-citation>
      </ref>
      <ref id="b17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nicolaou</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Estdale</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Tsatmali</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Herrero</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Thody</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <source>FEBS Lett</source>
          <year>2004</year>
          <volume>570</volume>
          <fpage>223</fpage>
          <lpage>226</lpage>
          <pub-id pub-id-type="pmid">15251468</pub-id>
        </element-citation>
      </ref>
      <ref id="b18">
        <label>18</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Ancans</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <year>2002</year>
          <publisher-name>University of Bradford</publisher-name>
          <comment>PhD Thesis</comment>
        </element-citation>
      </ref>
      <ref id="b19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kauser</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schallreuter</surname>
              <given-names>KU</given-names>
            </name>
            <name>
              <surname>Thody</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Gummer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tobin</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <source>J Invest Dermatol</source>
          <year>2003</year>
          <volume>120</volume>
          <fpage>1073</fpage>
          <lpage>1080</lpage>
          <pub-id pub-id-type="pmid">12787137</pub-id>
        </element-citation>
      </ref>
      <ref id="b20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ancans</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tobin</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Hoogduijn</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Smit</surname>
              <given-names>NP</given-names>
            </name>
            <name>
              <surname>Wakamatsu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Thody</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <source>Exp Cell Res</source>
          <year>2001</year>
          <volume>268</volume>
          <fpage>26</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="pmid">11461115</pub-id>
        </element-citation>
      </ref>
      <ref id="b21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Masoodi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nicolaou</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <source>Rapid Commun Mass Spectrom</source>
          <year>2006</year>
          <volume>20</volume>
          <fpage>3023</fpage>
          <lpage>3029</lpage>
          <pub-id pub-id-type="pmid">16986207</pub-id>
        </element-citation>
      </ref>
      <ref id="b22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoogduijn</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Smit</surname>
              <given-names>NP</given-names>
            </name>
            <name>
              <surname>van der Laarse</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>van Nieuwpoort</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Thody</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <source>Pigment Cell Res</source>
          <year>2003</year>
          <volume>16</volume>
          <fpage>127</fpage>
          <lpage>132</lpage>
          <pub-id pub-id-type="pmid">12622789</pub-id>
        </element-citation>
      </ref>
      <ref id="b23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Busca</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ballotti</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <source>Pigment Cell Res</source>
          <year>2000</year>
          <volume>13</volume>
          <fpage>60</fpage>
          <lpage>69</lpage>
          <pub-id pub-id-type="pmid">10841026</pub-id>
        </element-citation>
      </ref>
      <ref id="b24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bhuyan</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Badiner</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Barden</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <source>Cancer Res</source>
          <year>1986</year>
          <volume>46</volume>
          <fpage>1688</fpage>
          <lpage>1693</lpage>
          <pub-id pub-id-type="pmid">3456266</pub-id>
        </element-citation>
      </ref>
      <ref id="b25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Riley</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <source>Tohoku J Exp Med</source>
          <year>2004</year>
          <volume>204</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">15329457</pub-id>
        </element-citation>
      </ref>
      <ref id="b26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>CB</given-names>
            </name>
          </person-group>
          <source>J Clin Invest</source>
          <year>1995</year>
          <volume>95</volume>
          <fpage>1669</fpage>
          <lpage>1675</lpage>
          <pub-id pub-id-type="pmid">7706475</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec sec-type="supplementary-material">
      <title>Supporting Information</title>
      <p>Additional Supporting Information may be found in the online version of this article:</p>
      <p><bold>Appendix S1.</bold> Materials and methods.</p>
      <supplementary-material content-type="local-data" id="SD1">
        <media xlink:href="exd0019-0751-SD1.doc" xlink:type="simple" id="d32e1437" position="anchor" mimetype="application" mime-subtype="msword"/>
      </supplementary-material>
      <p>Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.</p>
    </sec>
  </back>
</article>
